CIK 1856083
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 82.45% | 53 |
| Unclassified | 8.88% | 5 |
| Health Care Providers & Services | 8.68% | 4 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | GH | Guardant Health, Inc. | Health Care | 6.36% |
| 2 | IMVT | Immunovant, Inc. | Health Care | 5.91% |
| 3 | TARS | Tarsus Pharmaceuticals, Inc. | Health Care | 5.21% |
| 4 | PCVX | Vaxcyte, Inc. | Health Care | 5.16% |
| 5 | GPCR | Structure Therapeutics Inc. | Health Care | 4.26% |
| 6 | AXSM | Axsome Therapeutics, Inc. | Health Care | 3.84% |
| 7 | APELLIS PHARMACEUTICALS INC | Unclassified | 3.76% | |
| 8 | OCUL | OCULAR THERAPEUTIX, INC | Health Care | 3.44% |
| 9 | VERA | Vera Therapeutics, Inc. | Health Care | 3.41% |
| 10 | ALMS | ALUMIS INC. | Health Care | 3.08% |
57/62 names classified · sector 91.1% of weight · industry 91.1% · mkt cap 89.0%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 91.1% of the book is sector-classified (unclassified names shown, never dropped).
Only 6% of book weight classified — the grid is NOT representative of the whole book.
Classified: 5.8% of book weight (4/58 names) · unclassified 94.2%: , GH, IMVT, TARS, PCVX, GPCR, AXSM, OCUL, VERA, ALMS +44 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | GHGUARDANT HEALTH INC | 3,338,241 | $308M | 6.4% | ADD 19% |
| 2 | IMVTIMMUNOVANT INC | 11,526,971 | $286M | 5.9% | HOLD |
| 3 | TARSTARSUS PHARMACEUTICALS INC | 3,600,000 | $253M | 5.2% | ADD 20% |
| 4 | PCVXVAXCYTE INC | 4,300,000 | $250M | 5.2% | ADD 7% |
| 5 | GPCRSTRUCTURE THERAPEUTICS INC | 4,279,848 | $206M | 4.3% | ADD 4% |
| 6 | AXSMAXSOME THERAPEUTICS INC. | 1,100,000 | $186M | 3.8% | TRIM −4% |
| 7 | APELLIS PHARMACEUTICALS INC | 4,532,374 | $182M | 3.8% | TRIM −42% |
| 8 | OCULOCULAR THERAPEUTIX INC | 19,686,282 | $167M | 3.4% | ADD 144% |
| 9 | VERAVERA THERAPEUTICS INC | 4,106,067 | $165M | 3.4% | ADD 46% |
| 10 | ALMSALUMIS INC | 6,772,595 | $149M | 3.1% | NEW |
| 11 | IONSIONIS PHARMACEUTICALS INC | 1,950,000 | $146M | 3.0% | ADD 15% |
| 12 | NUVLNUVALENT INC | 1,376,324 | $141M | 2.9% | NEW |
| 13 | ALKSALKERMES PLC | 3,590,323 | $127M | 2.6% | ADD 80% |
| 14 | CENTESSA PHARMACEUTICALS PLC | 3,158,041 | $125M | 2.6% | ADD 58% |
| 15 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 6,408,863 | $119M | 2.5% | ADD 39% |
| 16 | MAZEMAZE THERAPEUTICS INC | 3,477,562 | $104M | 2.1% | TRIM −18% |
| 17 | ORKAORUKA THERAPEUTICS INC | 2,034,203 | $100M | 2.1% | TRIM −6% |
| 18 | NRIXNURIX THERAPEUTICS INC | 6,345,244 | $98M | 2.0% | TRIM −10% |
| 19 | GMABGENMAB A/S | 3,663,250 | $98M | 2.0% | NEW |
| 20 | CYTKCYTOKINETICS INC | 1,374,320 | $91M | 1.9% | TRIM −59% |
| 21 | GRALGRAIL INC | 1,722,797 | $89M | 1.8% | ADD 68% |
| 22 | LBRXLB PHARMACEUTICALS INC | 3,352,804 | $83M | 1.7% | HOLD |
| 23 | MBXMBX BIOSCIENCES INC | 2,757,569 | $82M | 1.7% | TRIM −15% |
| 24 | BCAXBICARA THERAPEUTICS INC | 4,062,500 | $81M | 1.7% | ADD 55% |
| 25 | CMPSCOMPASS PATHWAYS PLC | 12,161,496 | $67M | 1.4% | ADD 66% |
| 26 | BMRNBIOMARIN PHARMACEUTICAL INC | 1,150,000 | $65M | 1.3% | TRIM −50% |
| 27 | BBIOBRIDGEBIO PHARMA INC | 841,445 | $62M | 1.3% | ADD 4% |
| 28 | IMCRIMMUNOCORE HLDGS PLC | 1,931,884 | $58M | 1.2% | TRIM −4% |
| 29 | TNGXTANGO THERAPEUTICS INC | 2,750,000 | $58M | 1.2% | ADD 12% |
| 30 | DFTXDEFINIUM THERAPEUTICS INC COM SHS | 3,000,000 | $57M | 1.2% | NEW |
| 31 | TERNS PHARMACEUTICALS INC | 1,073,877 | $57M | 1.2% | ADD 40% |
| 32 | GERNGERON CORP | 31,720,278 | $47M | 1.0% | TRIM −2% |
| 33 | ANIPANI PHARMACEUTICALS INC | 600,000 | $46M | 1.0% | ADD 26% |
| 34 | CRMDCORMEDIX INC | 6,274,076 | $43M | 0.9% | ADD 19% |
| 35 | ATAIATAIBECKLEY INC | 12,000,000 | $42M | 0.9% | NEW |
| 36 | CLDXCELLDEX THERAPEUTICS INC NEW | 1,283,979 | $41M | 0.8% | TRIM −32% |
| 37 | COGTCOGENT BIOSCIENCES INC | 1,000,000 | $38M | 0.8% | ADD 121% |
| 38 | CRVSCORVUS PHARMACEUTICALS INC | 2,491,539 | $36M | 0.8% | NEW |
| 39 | DYNDYNE THERAPEUTICS INC | 2,000,000 | $36M | 0.7% | TRIM −25% |
| 40 | SOLENO THERAPEUTICS INC | 1,078,710 | $36M | 0.7% | ADD 8% |
| 41 | ACRSACLARIS THERAPEUTICS INC | 9,345,000 | $35M | 0.7% | NEW |
| 42 | MANEVeradermics Inc | 500,000 | $32M | 0.7% | NEW |
| 43 | VSTMVERASTEM INC | 5,740,850 | $30M | 0.6% | HOLD |
| 44 | ENGENE HOLDINGS INC | 4,377,572 | $30M | 0.6% | HOLD |
| 45 | VRDNVIRIDIAN THERAPEUTICS INC | 1,393,944 | $27M | 0.6% | TRIM −45% |
| 46 | XFORX4 PHARMACEUTICALS INC | 6,339,535 | $26M | 0.5% | ADD 26% |
| 47 | SLDBSOLID BIOSCIENCES INC | 3,565,062 | $26M | 0.5% | NEW |
| 48 | ENTAENANTA PHARMACEUTICALS INC | 1,956,867 | $25M | 0.5% | HOLD |
| 49 | APGEAPOGEE THERAPEUTICS INC | 285,000 | $24M | 0.5% | NEW |
| 50 | KURAKURA ONCOLOGY INC | 2,643,542 | $21M | 0.4% | NEW |
| 51 | IPSCCENTURY THERAPEUTICS INC | 9,487,745 | $21M | 0.4% | NEW |
| 52 | BEAMBEAM THERAPEUTICS INC | 820,765 | $20M | 0.4% | NEW |
| 53 | CNTXCONTEXT THERAPEUTICS INC | 7,419,355 | $19M | 0.4% | HOLD |
| 54 | PSNLPERSONALIS INC | 3,000,000 | $19M | 0.4% | NEW |
| 55 | JANXJANUX THERAPEUTICS INC | 1,187,290 | $17M | 0.3% | ADD 1225% |
| 56 | PMNPROMIS NEUROSCIENCES INC | 835,655 | $11M | 0.2% | NEW |
| 57 | CBIOCRESCENT BIOPHARMA INC. | 453,686 | $8M | 0.2% | HOLD |
| 58 | IVAINVENTIVA SA | 1,222,453 | $7M | 0.1% | ADD 149% |
| 59 | LRMRLARIMAR THERAPEUTICS INC | 1,500,000 | $7M | 0.1% | NEW |
| 60 | HELPCYBIN INC | 1,313,137 | $6M | 0.1% | TRIM −29% |
| 61 | BLLNBILLIONTOONE INC | 50,000 | $4M | 0.1% | HOLD |
| 62 | ALGSALIGOS THERAPEUTICS INC | 444,110 | $3M | 0.1% | HOLD |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| GHGUARDANT HEALTH INC | 6.4M | 5.4M | 4.3M | 4.2M | 2.8M | 3.3M | $308M |
| IMVTIMMUNOVANT INC | 6.0M | 9.5M | 9.5M | 9.7M | 11.5M | 11.5M | $286M |
| TARSTARSUS PHARMACEUTICALS INC | — | 1.5M | 1.8M | 3.0M | 3.0M | 3.6M | $253M |
| PCVXVAXCYTE INC | — | 750K | 2.1M | 3.0M | 4.0M | 4.3M | $250M |
| GPCRSTRUCTURE THERAPEUTICS INC | 2.8M | 4.1M | 5.1M | 4.2M | 4.1M | 4.3M | $206M |
| AXSMAXSOME THERAPEUTICS INC. | — | — | 801K | 900K | 1.1M | 1.1M | $186M |
| APELLIS PHARMACEUTICALS INC | 4.3M | 5.0M | 7.0M | 8.0M | 7.8M | 4.5M | $182M |
| OCULOCULAR THERAPEUTIX INC | 12.8M | 14.3M | 14.3M | 11.9M | 8.1M | 19.7M | $167M |
| VERAVERA THERAPEUTICS INC | — | — | — | — | 2.8M | 4.1M | $165M |
| ALMSALUMIS INC | — | — | — | — | — | 6.8M | $149M |
| IONSIONIS PHARMACEUTICALS INC | 1.9M | 4.6M | 4.9M | 3.8M | 1.7M | 1.9M | $146M |
| NUVLNUVALENT INC | — | — | — | — | — | 1.4M | $141M |
| ALKSALKERMES PLC | — | — | — | — | 2.0M | 3.6M | $127M |
| CENTESSA PHARMACEUTICALS PLC | 1.4M | — | 500K | — | 2.0M | 3.2M | $125M |
| MLTXMOONLAKE IMMUNOTHERAPEUTICS | — | — | — | — | 4.6M | 6.4M | $119M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
